|
PRINTVERSIE PAGINA PRINTVERSIE DAGFORMULIER BESTELLEN VAN DE VOEDINGSUPPLEMENTEN |
||
1.
HET PROGRAMMA
‘DE WEG TERUG’ 2.
AANBEVOLEN
VOEDINGSSUPPLEMENTEN VOOR HET PROGRAMMA ‘DE WEG TERUG’ 3.
BIJWERKINGEN EN
ONTWENNINGSVERSCHIJNSELEN VAN PSYCHIATRISCHE MEDICIJNEN 4.
DE
VOORBEREIDENDE FASE ZET DE EERSTE STAP OP DE WEG TERUG 6.
HET AFBOUWEN VAN
BENZODIAZEPINEN, ANTI-EPILEPTICA, KALMERENDE MIDDELEN EN SLAAPMIDDELEN 7.
DE WEG TERUG VAN
ANTIPSYCHOTICA, ANTIDEPRESSIVA EN ADHD MEDICATIE: DE VOORBEREIDENDE FASE 8.
HET AFBOUWEN VAN
ANTIPSYCHOTICA, ANTIDEPRESSIVA EN ADHD MEDICATIE 9.
DE WEG TERUG VAN
MEERDERE MEDICIJNEN 10. ALS JE AL BENT BEGONNEN MET AFBOUWEN OF AL MET DE MEDICATIE BENT GESTOPT 11. ALS JE NOOIT PSYCHIATRISCHE MEDICATIE HEBT GEBRUIKT 12, HOE KUN JE AFKOMEN VAN DOOR MEDICIJNEN VEROORZAAKT OVERGEWICHT 13. ALS JE DE MEDICATIE VOLLEDIG HEBT AFGEBOUWD |
Hoofdstuk
Vijftien REFERENTIES: Bloom
FE, Kupfer DJ, editors. Psychopharmacology: The fourth generation of
progress. Eliot
RS, Clayton FC, Pieper GM, Todd GL. Influence of environmental stress on
pathogenesis of sudden cardiac death. Fed Proc 1977; 36: 1719–24. Krantz
DS, Kop WJ, Miller
AH. Neuroendocrine and immune system interactions in stress and
depression. Psychiatr Clin North Am 1998; 21: 443–63. Corrigan
FM. Depression: immunological resignation of the will to live? Med
Hypotheses 1998; 50: 9–18. Gorman
JM, Kertzner R. Psychoneuroimmunology and HIV infection. J
Neuropsychiatry Clin Neurosci 1990; 2: 241–52. Checkley
S. The neuroendocrinology of depression and chronic stress. Br Med Bull
1996; 52: 597–617. Spiegel
D. Cancer and depression. Br J Psychiatry Suppl 1996; 30: 109–16. File
SE. Recent
development in anxiety, stress, and depression. Pharmacol Biochem Behav 1996; 54: 3–12. Paykel
ES. Life
stress, depression, and attempted suicide. J Human Stress 1976; 2:
3–12. Passchier
J. A critical note on psychophysiological stress research into migraine
patients. Cephalalgia 1994; 14: 194–8. Marshall
PS. Allergy and depression: a neurochemical threshold model of the
relation between the illnesses. Psychol Bull 1993; 113: 23–43. Hordern
A. Psychopharmacology-some historical considerations. In: Joyce CRB,
editor. Psychopharmacology dimensions and perspectives. Ayd
Jr FJ, Blackwell B, editors. Discoveries in biological psychiatry. Swazey
JP. Chlorpromazine in psychiatry. A study of therapeutic innovation. Lewin
L. Phantastica, narcotic and stimulating drugs. New York, EP Dutton
& Co; 1964. p. 335. Klüver
H. Mescal and mechanisms of hallucinations. Chicago, Efron
DH, Holmstedt B, Siva
Sankar DV. LSD:
A total study. Stillman
RC, Willette RE, editors. The psychopharmacology of hallucinogens. Schultes
RE, Hofmann A. Plants of the gods. Origins of hallucinogenic use. Pletscher
A, Ladewig D, editors. 50 Years of LSD: current status and perspectives
of hallucinogens. Macht
DI, Mora CF. Effect
of opium alkaloids on the behavior of rats in the circular maze. J
Pharmacol Exp Ther 1921; 16: 219–35. Bovet
D. Introduction to antihistamine agents and antergan derivatives. Ann NY
Acad Sci 1950; 50: 1089–126. Goodman
LS, Gilman A. The pharmacological basis of therapeutics. 2nd ed. Winter
C, Flataker L. The effect of antihistaminic drugs on the performance of
trained rats. J Pharmacol Exp Ther 1951; 101: 156–62. Courvoisier
S. Pharmacodynamic basis for the use of chlorpromazine in psychiatry. J
Clin Exp Psychopathol 1956; 17: 25–37. Laborit
H, Huguenard P. L’hibernation artificielle par moyens
pharmacodynamiques et physiques en chirurgie. J Chir 1951a; 67:
631–41. Laborit
H, Huguenard P. L’hibernation artificielle par moyens
pharmacodynamiques et physiques. Presse Méd 1951b; 59: 1329. Laborit
H, Huguenard P, Alluaume R. Un nouveau stabilisateur végétatif (le
4560 RP). Presse Méd 1952; 60: 206–8. Delay
J, Deniker P. Le traitement des psychoses par une méthode neurolytique
dérivée de l’hibernothérapie. (Le 4560 R.P. utilisé seul. En cure
prolongée et continue.) CR Congrès Méd Alién Neurol France 1952; 50:
497–502. Deniker
P. Introduction of neuroleptic chemotherapy into psychiatry. In: Ayd FJ,
Blackwell B, editors. Discoveries in biological psychiatry.
Philadelphia, JB Lippincott Co; 1970. p. 155–64. Gordon
M, Craig PN, Zirkle CL. Molecular modifications in the development of
phenothiazine drugs. In: Molecular modification in drug design. Adv
Chem 1964; 45: 140–47. Janssen
PAJ. The
butyrophenone story. In: Ayd FJ Jr, Blackwell B, editors. Discoveries in
biological psychiatry. Philadelphia, JB Lippincott Co; 1970. p.
165–79. Schwartz
H. Breakthrough: the discovery of modern medicines at Janssen. Corssen
G, Domino EF, Sweet RB. Neurolept
analgesia and anesthesia. Anesth
Analg 1964; 43: 748–63. Janssen
PAJ, Awouters FHL. Antipsychotic
agents. In: Hofmann
A. The discovery of LSD and subsequent investigations on naturally
occurring hallucinogens. In: Ayd FJ Jr, Blackwell B, editors.
Discoveries in biological psychiatry. Philadelphia, JB Lippincott Co;
1970. p. 91–106. Martin
WR, Sloan JW. Effects of infused tryptamine in man. Psychopharmacologia
(Berl) 1970; 18: 231–37. Domino
EF. The
indole hallucinogen model: is it worth pursuing? In: Sudilovsky A,
Gershon S, Beer B, editors. Predictability in psychopharmacology:
preclinical and clinical correlates. Kuhn
R. The treatment of depressive states with G 22355 (imipramine
hydrochloride). Am
J Psychiatry 1958; 115: 459–64. Kuhn
R. The imipramine story. In: Ayd FJ, Blackwell B, editors. Discoveries
in biological psychiatry. Philadelphia, JB Lippincott Co; 1970. p.
205–17. Coppen
A. Depressive states and indolealkylamines. Adv Pharmacol 1968; 6:
283–91. Isaac
L, Goth A. Interaction of antihistaminics with norepinephrine uptake: a
cocaine-like effect. Life Sci 1965; 14: 1899–904. Isaac
L, Goth A. The mechanism of the potentiation of norepinephrine by
antihistaminics. J Pharmacol Exp Ther 1967; 156: 463–8. Barnett
A, Taber RI, Roth FE. Activity of antihistamines in laboratory
antidepressant tests. Int
J Neuropharmacol 1969; 8: 73–9. Carlsson
A, Linqvist M. Central and peripheral monoaminergic membrane-pump
blockade by some addictive analgesics and antihistamines. J Pharm
Pharmacol 1969; 21: 460–4. Lapin
IP, Oxenkrug GF. Intensification of the central serotonineric processes
as a possible determinant of the thymoleptic effect. Lancet 1969; 1:
132–6. Wong,
DT, Bymaster FP, Engleman EA. Prozac (fluoxetine, Lilly 110140), the
first selective serotonin uptake inhibitor and an antidepressant drug:
twenty years since its first publication. Life Sci 1995; 57: 411–41. Wong
DT, Bymaster FP, Horng JS, Molloy BB. A new selective inhibitor for
uptake of serotonin into synaptosomes of rat brain:
3-(p-trifluoromethylphenoxy) N-methyl-3- phenylpropylamine. J Pharmacol
Exp Ther 1975; 193: 804–11. Schatzberg
AF, Schildkraut JJ. Recent studies on norepinephine systems in mood disorders. In: Bloom FE,
Kupfer DJ, editors. Psychopharmacology: the fourth generation of
progress. Willmer
P. Dopaminergic mechanisms in depression and mania. In: Bloom FE, Kupfer
DJ, editors. Psychopharmacology: the fourth generation of progress. Maes
M, Meltzer HY. The
serotonin hypothesis of major depression. In: Bloom FE, Kupfer DJ,
editors. Psychopharmacology: the fourth generation of progress. Janowsky
DS, Overstreet, DH. The role of acetylcholine mechanisms in mood
disorders. Chapter 82.In: Bloom FE, Kupfer DJ, editors
Psychopharmacology The Fourth Generation of Progress. Holsboer
F. Neuroendocrinology of mood disorders. Chapter 83.In: Bloom FE, Kupfer
DJ, editors Psychopharmacology The Fourth Generation of Progress. Plotsky
PM, Owens MJ, Nemeroff CB. Neuropeptide
alterations in mood disorders. Chapter 84.In: Bloom FE, Kupfer DJ
editors Psychopharmacology The Fourth Generation of Progress. Irwin
M. Psychoneuroimmunology of depression. In: Bloom FE, Kupfer DJ,
editors. Psychopharmacology: the fourth generation of progress. Wirz-Justice
A. Biological rhythms in mood disorders. In: Bloom FE, Kupfer DJ,
editors. Psychopharmacology: the fourth generation of progress. Parry
BL. Mood disorders linked to the reproductive cycle in women. In: Bloom
FE, Kupfer DJ, editors. Psychopharmacology: the fourth generation of
progress. Nathan
KI, Musselman DL, Schatzberg AF, Nemeroff CB. Biology
of mood disorders. In: Schatzberg
AF, Nemeroff CB, editors. Textbook of psychopharmacology. Washington, The American Psychiatric
Press; 1995. p. 439–77. Prog
Neuropsychopharmacol Biol Psychiatry. 2005
Sep;29(7):1140-51. Nutrition
and Neurocognition Laboratory and Vitamin Metabolism and Aging
Laboratory, The Cochrane
Database Syst Rev. 2003;(4):CD004514. Folic acid with or without vitamin
B12 for cognition and dementia. Dept. of Clinical Geratology, Cochrane
Dementia and Cognitive Improvement Group, Radcliffe Infirmary, Annu
Rev Nutr. 1999;19:217-46. Homocysteine metabolism. Clin
Chem Lab Med. 2003 Nov;41(11):1392-403 DACH-LIGA homocysteine (German,
Austrian and Swiss homocysteine society): consensus paper on the
rational clinical use of homocysteine, folic acid and B-vitamins in
cardiovascular and thrombotic diseases: guidelines and recommendations. Recenti
Prog Med. 2004 Jul-Aug;95(7-8):371-5 Hyperhomocysteinemia in neurologic
diseases Altern
Med Rev. 2003 Feb;8(1):7-19 The methionine-homocysteine cycle and its
effects on cognitive diseases.Thorne Research, WMJ.
1999 Dec;98(8):51-4 Hyperhomocysteinemia: an additional cardiovascular
risk factor. Medical Ann
Clin Biochem. 2003 Jan;40(Pt 1):46-59 Genetics of hyperhomocysteinaemia
in cardiovascular disease. Laboratory of Pediatrics and Neurology,
University Medical Centre Nutr
Clin Care. 2002 May-Jun;5(3):124-32 Folate, homocysteine, and
neurological function. Nutritional Epidemiology Program, Jean Mayer USDA
Human Nutrition Research Center on Aging, Tufts University, 711
Washington Street, 9th Floor, Boston, MA Trends
Neurosci. 2003 Mar;26(3):137-46 Folate and homocysteine metabolism in
neural plasticity and neurodegenerative disorders. Laboratory of
Neurosciences, National Institute on Aging Gerontology Research Center,
National Institutes of health, 5600 Nathan Shock Drive, Baltimore, MD CMAJ.
2000 Jul 11;163(1):21-9. Preventive health care, 2000 update: screening
and management of hyperhomocysteinemia for the prevention of coronary
artery disease events. The Canadian Task Force on Preventive Health
Care. J
Neurochem. 2002 Jan;80(1):101-10 Dietary folate deficiency and elevated
homocysteine levels endanger dopaminergic neurons in models of
Parkinson's disease. Hematology
(Am Soc Hematol Educ Program). 2003;:62-81 Update on cobalamin, folate,
and homocysteine Eur
J Pediatr. 1998
Apr;157 Suppl 2:S122-6 Relevance of vitamins, homocysteine and other
metabolites in neuropsychiatric disorders. Department of Medicine,
University of Clin
Chem Lab Med. 2003 Nov;41(11):1427-34 The role of genetic factors in the
development of hyperhomocysteinemia. Department of Clinical Chemistry, Int
J Geriatr Psychiatry. 2002
Sep;17(9):859-64 Homocysteine in neuropsychiatric disorders of the
elderly Neuropsychiatric Institute, Prince of Wales Hospital, Sydney,
Australia Lancet
Neurol. 2003 Jul;2(7):425-8 Homocysteine and Alzheimer's disease. Jean
Mayer United States Department of Arch
Neurol. 2000 Oct;57(10):1422-7 Homocysteine and neurologic disease. Nutr
Rev. 1996 Dec;54(12):382-90 Folate, vitamin B12, and neuropsychiatric
disorders. Kimberly H. Courtwright and Joseph W. Summers Institute of
Metabolic Disease, Alcohol
Clin Exp Res. 2000 Mar;24(3):259-64 Effect of chronic alcohol
consumption on total plasma homocysteine level in rats. Department of
Gastroenterology, Stiftsklinik Augustinum, Arch
Gen Psychiatry. 2003 Jun;60(6):618-26 Folate, vitamin B12, homocysteine,
and the MTHFR 677C->T polymorphism in anxiety and depression: the
Hordaland Homocysteine Study. J
Nutr Health Aging. 2002;6(1):39-42 Folate, vitamin B12 and vitamin B6
and one carbon metabolism. JM Hypertension.
2001 Nov;38(5):1217-21 Hyperhomocysteinemia in liver cirrhosis:
mechanisms and role in vascular and hepatic fibrosis. Division de
Hepatologia y Terapia Genica, Departamento de Medicina Interna, Facultad
de Medicina, Universidad de Navarra, J
Neurol Neurosurg Psychiatry. 2000 Aug;69(2):228-32 Homocysteine, folate,
methylation, and monoamine metabolism in depression. Alcohol.
2005 Apr;35(3):227-34 Role of methionine adenosyltransferase and S-adenosylmethionine
in alcohol-associated liver cancer. USC Research Center for Liver
Diseases, USC-UCLA Research Center for Alcoholic Liver and Pancreatic
Diseases, Keck School of Medicine USC, Los Angeles, CA Alcohol.
2005 Apr;35(3):205-11 Alcohol and pancreatic cancer Department
of Medicine, Toxicol
Appl Pharmacol. 2005 Jul 19 Epoxidation of the methamphetamine pyrolysis
product, trans-phenylpropene, to trans-phenylpropylene oxide by CYP
enzymes and stereoselective glutathione adduct formation. Department of
Basic Pharmaceutical Sciences, Hepatology.
2005 Aug;42(2):400-10 Induction of cytochrome P450 2E1 increases
hepatotoxicity caused by Fas agonistic Jo2 antibody in mice. Brain
Res. 2005 Aug 9;1052(2):202-11 Mitochondrially targeted vitamin E and
vitamin E mitigate ethanol-mediated effects on cerebellar granule cell
antioxidant defense systems. Neurosci
Lett. 2005 Mar 11;376(2):98-101 Melatonin enhances the in vitro and in
vivo repair of severed rat sciatic axons. Section of Neurobiology, The J
Neural Transm. 2005 Mar;112(3):349-58. Epub 2005 Jan 24 Antioxidant
capacity of the neurohormone melatonin. J
Pineal Res. 2005 Jan;38(1):1-9 Melatonin mitigates mitochondrial
malfunction. Pol
J Pharmacol. 2004
Mar-Apr;56(2):159-70 Pharmacological utility of melatonin in reducing
oxidative cellular and molecular damage. Department of Cellular and
Structural Biology, University of Texas Health Science Center, 7703
Floyd Curl Drive, MC 7762 San Antonio, TX Mayo
Clin Proc. 2005 Oct;80(10):1307-15 Cardiovascular toxicities of
performance-enhancing substances in sports. Department of Clinical Care
Research, Institute for Clinical Research and Health Policy Studies,
Tufts University-New England Medical Center, Boston, MA The
Journal of the American Medical Association - JAMA - Recombinant Leptin for Weight Loss in Obese and Lean
Adults A Randomized, Controlled, Dose-Escalation Trial Neurol Psychiatry 2001 -
Weight changes during pharmacological treatment are a well-known
phenomenon and they have been an object of research since the 1950's. Department of Neuroscience, EFA Sciences LLC, Norwood, Massachusetts
- Obesity may be a low-grade systemic
inflammatory disease Behavioral
Psychopharmacology Research Laboratory, Britton,
S.W. & Silvette, H. The effects of cortico-adrenal extract on
carbohydrate metabolism in normal animals. American Journal of
Physiology, 1932, 100, 693-700. Bunney,
W.E., Jr., Mason, J.W., Roatch, J.F., & Bunney,
W.E., Jr., Mason, J.W., & Cahill,
G.F. Advances in enzyme regulations. Vol. 2. Connason,
B.F., & Ryberg, R.A. Stress conditioning in schizophrenia and
neurotic disorders, Diseases of the Nervous System. 1957, 18, 7. Curtis,
G. C., Cleghorn, R.A., & Sourkes, T.L. The relationship between
affect and the excretion of adrenaline, noradrenaline, and
17-hydroxycorticosteroids. Journal of Psychosomatic Research, 1960,
4, 176-184. David
H. P. Streeten, MB, DPhil, FRCP. The Nature of Chronic Fatigue.
JAMA. 1998;280:1094-1095. Department
of Pharmacology, Center for Serotonin Disorders Research, Loyola
University of Chicago, Stritch School of Medicine, Maywood, Illinois.
Serotonin and the neuroendocrine regulation of the
hypothalamic--pituitary-adrenal axis in health and disease. 2003;66:189-255. Department
of Pharmacology, Department
of Pharmacology, Department
of Physiology, Department
of Psychiatry, Department
of Psychiatry, Departments of Psychology and Biology and Centers for Neuroscience and
Life Sciences Research, The University at Developmental
Endocrinology Branch, National Institute of Child Health and Human
Development, Division
of Psychological Medicine, Section of Neurobiology of Mood Disorders,
Institute of Psychiatry, Graham,
B.F., & R.A. Cleghorn, R.A. Changes in the circulating leukocytes
following electrically induced convulsions in man. Journal of
Clinical Endocrinology, 1951, 11, 1469. Harvard Encyclopedia, 1891 Volume 23. Hoffer,
A., Osmond, H., Callbeck, M.J. & Kahan, Ingle,
D.J. The chemistry and physiology of hormones. Institute of Endocrinology and Haematology, International
Medical Director CNS & Cardiovascular, Organon Inc., 375 Mt.
Pleasant Avenue, Larsen,
Virginia L. Physical characteristics of disturbed adolescents.
Archives of General Psychiatry, 1964, 10, 55-64. Long,
C.N.H., Katzin, B. & Fry, E.G. The adrenal cortex and
carbohydrate metabolism. Endocrinology, 1950, 26, 309. Lorah
D. Dorn, PhD, RN, CPNP; Stacie F. Hitt, PhD, RN; Deborah Rotenstein, MD.
Biopsychological
and Cognitive Differences in Children With Premature vs On-Time
Adrenarche. Arch
Pediatr Adolesc Med. 1999;153:137-146. Lynne
Lamberg. Psychiatrists
Explore Legacy of Traumatic Stress in Early Life.
JAMA. 2001;286:523-526. Meyer,
A. Commonsense psychiatry. Neuroendocrinology
Dept., Medical Centre of Postgraduate Education, Marymoncka 99, 01-813 Paul
S. Ciechanowski, MD, MPH; Wayne J. Katon, MD; Joan E. Russo, PhD. Depression
and Diabetes Impact of Depressive Symptoms on Adherence, Function, and
Costs Arch
Intern Med. 2000;160:3278-3285. Persky,
H., Maroc, J., Conrad, E. & Den Breeijen, A. Blood corticotropin
and adrenal weight-maintenance factor levels of anxious patients and
normal subjects. Psychosomatic Medicine, 1959, 21, 379-386. Plager,
J.E. & Matsui, N. In vitro demonstration of the anti-insulin
action of cortisol on glucose metabolism. Endocrinology, 1966, 78,
1154. Portis,
Portis,
S.A. & Zitman, I.H. Mechanism of fatigue in neuropsychiatric
patients, Journal of the American Medical Association, 1943, 121,
569. Physician's
guidelines of diagnosis and treatment of hypoglycemia or the
hypoadrenocortical state. The Hypoglycemia Foundation, Psychobiology Research Group, School of Neurology, Neurobiology and
Psychiatry, Royal Victoria Infirmary, Newcastle-upon-Tyne, UK. Evidence
of basal pituitary-adrenal overactivity in first episode, drug naive
patients with schizophrenia. 2004 Sep;29(8):1065-70. Roberts,
H.J. The roles of diabetogenic hyperinsulinism in pathogenesis of
prostatic hyperplasia and malignancy. Journal of the American
Geriatrics Society, 1966, 14, 795. Robin
McKenzie, MD; Ann O'Fallon, RN; Janet Dale, RN, MPH; Mark Demitrack, MD;
Geetika Sharma, MD; Maria Deloria; Diego Garcia-Borreguero, MD; William
Blackwelder, PhD; Stephen E. Straus, MD. Low-Dose Hydrocortisone for Treatment of Chronic Fatigue Syndrome.
JAMA. 1998;280:1061-1066. Section
on Clinical Pharmacology, National Institute of Mental Health, Selye,
H. The general adaptation syndrome and the diseases of adaptation.
Journal of Clinical Endocrinology, 1946, 6, 117. Simon,
G.B. & Gillies, S.M. Some physical characteristics of a group of
psychotic children. British Journal of Psychiatry, 1964, 110,
104-107. Stern
H. Serotonin, and its effects on the pituitary-adrenal axis in
depression. 1970;29(1):24-30. Suicidal Risk in Antidepressant Drug Trials Arch
Gen Psychiatry. 2006;63:246-248. Suwa,
N., Yamashita, Tintera,
J.W. The hypoadrenocortical state and its management. Tintera,
J.W., Stabilizing homeostasis in the recovered alcoholic through
endocrine therapy: Evaluation of the hypoglycemic factor. Journal of
the American Geriatrics Society, 1966, 14, 126. Tintera,
J.W. & Lovell, H.W. Endocrine treatment of alcoholism.
Geriatrics, 1949, 4, 274. University
Department of Medicine, Bertilsson
L, Dahl ML, Dalen P, Al-Shurbaji A: Molecular genetics of CYP2D6:
clinical relevance with focus on psychotropic drugs. Br J Clin Pharmacol
2002 Feb;53(2):111-122 Cozza
KL, De
Morais SM, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein
JA, The major genetic defect responsible for the polymorphism of S-mephenytoin
metabolism in humans. J Biol Chem. 1994 Jun 3;269(22):15419-22 Xiao
ZS, Goldstein JA, Xie HG, Blaisdell J, Wang W, Jiang CH, Yan FX, He N,
Huang SL, Xu ZH, Zhou HH. Differences in the incidence of the CYP2C19
polymorphism affecting the S-mephenytoin phenotype in Chinese Han and
Bai populations and identification of a new rare CYP2C19 mutant allele.
J Pharmacol Exp Ther. 1997 Apr;281(1):604-9. Aynacioglu
AS, et al. Frequency of cytochrome P450 CYP2C9 variants in a Turkish population and
functional relevance for phenytoin. Br J Clin Pharmacol 1999;
48(3):409-415 Chida
M, Yokoi T, Fukui T, Kinoshita M, Yokota J, Kamataki T. Detection of
three genetic polymorphisms in the 5'-flanking region and intron 1 of
human CYP1A2 in the Japanese population. Jpn J Cancer Res. 1999
Sep;90(9):899-902 Bertilsson
L. et.al. Molecular basis for rational megaprescribing in ultrarapid
hydroxylators of debrisoquine. Lancet 1993;341:63. Brockmoller
J et.al. Pharmacogenetic diagnosis of cytochrome P450 polymorphisms in
clinical drug development and in drug treatment. Pharmacogenetics.
2000:1:125-51. Evans,
William E. and McLeod, Howard L. Pharmacogenomics — Drug Disposition,
Drug Targets, and Side Effects. Guttmacher,
Alan E. and Collins, Francis S. Genomic Medicine — A Primer. Heim
M and Meyer UA. Genotyping of poor metabolisers of debrisoquine by
allele-specific PCR amplification. Lancet 1990; 336:529-532. Kalow
W and Grant DM. Pharmacogenetics - The metabolic and molecular bases of
inherited disease. 1995. Scriver CR, et al, eds. Kirchheiner
J et al. Pharmacogenetics of antidepressants and antipsychotics: the contribution
of allelic variations to the phenotype of drug response. Molecular
Psychiatry 2004 9, 442-473 Linder
MW, Valdes R, Jr. Genetic mechanisms for variability in drug response
and toxicity. J Anal Toxicol 2001;25:405-13. Linder MW, Valdes R, Jr.
Pharmacogenetics
in the practice of laboratory medicine. Mol
Diagn 1999;4:365-79. Linder MW, Valdes R, Jr.
Fundamentals
and applications of pharmacogenetics for the clinical laboratory. Ann
Clin Lab Sci 1999;29:140-9. Steen VM, et al. Detection
of the poor metabolizer-associated CYP2D6(D) gene deletion by long-PCR
technology. Pharmacogenetics
1995; 5:215-223. Weinshilboum,
Richard. Inheritance and Drug Response New Wolf
CR and Smith G. Pharmacogenetics. Br Med Bull 1999; 55(2):366-386. Ambrosone,
C. B., J. L. Freudenheim, et al. (1999). "Manganese superoxide dismutase (MnSOD)
genetic polymorphisms, dietary antioxidants, and risk of breast
cancer." Cancer Res 59(3): 602-6. Bailey,
L.B., J.F. Gregory . (1999)."Polymorphisms of
methylenetetrahydrofolate reductase and other enzymes: metabolic
significance, risks and impact on folate requirement." J Nutr
129(5): 919-22 Bailey,
L.B., J.F. Gregory. (1999). "Folate metabolism and
requirements." J Nutr 129(4): 779-82 Borgstahl,
G. E., H. E. Parge, et al. (1996). "Human mitochondrial manganese
superoxide dismutase polymorphic variant Ile58Thr reduces activity by
destabilizing the tetrameric interface." Biochemistry 35(14):
4287-97. Bosron,
W.F., L. Ting-Kai (1986). "Genetic polymorphism of human liver
alcohol and aldehyde dehydrogenases, and their relationship to alcohol
metabolism and alcoholism." Hepatology 6(3): 502 - 510 Chango,
A., F. Boisson, et al. (2000). "The effect of 677C-->T and
1298A-->C mutations on plasma homocysteine and
5,10-methylenetetrahydrofolate reductase activity in healthy
subjects." Br J Nutr 83(6):
593-6. Cheng,
T., Z. Zhu et al. (2001). "Effects of multinutrient supplementation
on antioxidant defense systems in healthy human beings." J
Nutr Biochem 12(7): 388-395. Chistyakov,
D. A., Savost'anov, et al. (2001). "Polymorphisms in the Mn-SOD and EC-SOD
genes and their relationship to diabetic neuropathy in type 1 diabetes
mellitus." BMC Med Genet 2(1): 4. Cosma,
G., F. Crofts, et al. (1993). "Relationship between genotype and
function of the human CYP1A1 gene." J Toxicol Environ Health
40(2-3): 309-16. Crabb, D. W., H. J.
Edenberg, et al. (1989).
"Genotypes for aldehyde dehydrogenase deficiency and alcohol
sensitivity. The inactive ALDH2(2) allele is dominant." J
Clin Invest 83(1): 314-6. Crofts,
F., E. Taioli, et al. (1994). "Functional significance of different
human CYP1A1 genotypes." Carcinogenesis 15(12): 2961-3. Cronin
K A, Krebs-Smith S M, Feuer E J, Troiano R P, Ballard-Barbash R. (2001
May). "Evaluating the impact of population changes in diet,
physical activity, and weight status on population risk for colon cancer
( Dekou,
V., P. Whincup, et al. (2001). "The effect of the C677T and A1298C
polymorphisms in the methylenetetrahydrofolate reductase gene on
homocysteine levels in elderly men and women from the British regional
heart study." Atherosclerosis 154(3): 659-66. Department
of Health, Fennell,
T. R., J. P. MacNeela, et al. (2000). "Hemoglobin adducts from acrylonitrile and
ethylene oxide in cigarette smokers: effects of glutathione S-transferase
T1-null and M1-null genotypes." Cancer Epidemiol Biomarkers Prev
9(7): 705-12. Fohr
I.O., R. Prinz-Lnagenohl, et al. (2002).
"10-Methyleneterahydrofolate reductase genotype determines the
plasma homocysteine-lowering effect of supplementation with
5-methyltetrahydrofolate or folic acid in healthy young women."
American Journal of Clinical Nutrition 75: 275 - 82 Fontana,
R. J., K. S. Lown, et al. (1999). "Effects of a chargrilled meat diet on
expression of CYP3A, CYP1A, and P- glycoprotein levels in healthy
volunteers." Gastroenterology 117(1): 89-98. Fowke
JH, Longcope C, Hebert JR. (2000) "Brassica Vegetable Consumption
Shifts Estrogen Metabolism in Healthy Postmenopausal Women." Cancer
Epidemiol Biomarkers Prev 9(8):773-779. Gao,
X., T. Albena, Dinkova-Kostova, P. Talalay (2001). "Powerful and
prolonged protection of human retinal pigment epithelial cells,
keratinocytes, and mouse leukemia cells against oxidative damage: The
indirect antioxidant effects of sulforaphane." PNAS 98(26): 15221 - 15226. Getahun
SM, Chung FL.. (1999). "Conversion of glucosinolates to isothiocyanates in humans
after ingestion of cooked watercress." Cancer Epidemiology
Biomarkers Preview 8(5): 447 - 451. Giovannucci,
E. (1999). "Nutritional factors in human cancers." Adv Exp Med
Biol 472: 29-42. Giovannucci,
E. M.J. Stampfer, et al. (1998). "Multivitamin use, folate, and
colon cancer in women in the Nurses' Health Study." Annals of
Internal Medicine 129: 517 – 524 Guyonnet,
D., Belloir, C., Suschetet, M., Siess, M.H., Le Bon, A.M. (2001)
Antimutagenic activity of organosulfur compounds from Allium is
associated with phase II enzyme induction. Mut Res 496(1-2)135-142 Harada,
S., D. P. Agarwal, et al. (2001). "Metabolic and ethnic determinants of
alcohol drinking habits and vulnerability to alcohol-related
disorder." Alcohol Clin Exp Res 25(5 Suppl ISBRA): 71S-75S. Inoue,
K., T. Asao, et al. (2000). "Ethnic-related differences in the
frequency distribution of genetic polymorphisms in the CYP1A1 and CYP1B1
genes in Japanese and Caucasian populations." Xenobiotica
30(3): 285-95.1. Jacques,
P. F., A. G. Bostom, et al. (1996). "Relation between folate status, a common
mutation in methylenetetrahydrofolate reductase, and plasma homocysteine
concentrations." Circulation 93(1): 7-9. Kang,
Z. C., S. J. Tsai, et al. (1999). "Quercetin inhibits benzo[a]pyrene-induced
DNA adducts in human Hep G2 cells by altering cytochrome P-450 1A1 gene
expression." Nutr Cancer 35(2): 175-9. Lampe,
J.W., C.Chen et al. (2000). "Modulation of human glutathione S-transferases
by botanically defined vegetable diets." Cancer Epidemiology
Biomarkers Preview 9(8):787-93. Landi,
S. (2000). "Mammalian class theta GST and differential
susceptibility to carcinogens: a review." Mutat Res 463(3): 247-83. Lanza,
E; Schatzkin, A, Daston, C, Corle, D; Freedman, L, Ballard-Barbash, R,
Caan, B, Lance, P, Marshall, J, Iber, F, Shike, M, Weissfeld, J,
Slattery, M, Paskett, E, Mateski, D, Albert, P, and the PPT Study Group
(2001). "Implementation of a 4-y, high-fiber,
high-fruit-and-vegetable, low-fat dietary intervention: results of
dietary changes in the Polyp Prevention Trial 1, 2" Am J Clin Nutr
74:387-401 Lin
HJ, Probst-Hensch NM, Louie AD, Kau IH, Witte JS, Ingles SA, Frankl HD,
Lee ER, Haile RW. (1998 Aug). "Glutathione transferase null
genotype, broccoli, and lower prevalence of colorectal adenomas."
Cancer Epidemiol Biomarkers Prev 7(8):647-52. London,
S. J., J. M. Yuan, et al. (2000). "Isothiocyanates, glutathione S-transferase
M1 and T1 polymorphisms, and lung-cancer risk: a prospective study of
men in Lutz,
W. K. (1999). “Carcinogens in the diet vs overnutrition. Individual dietary habits,
malnutrition, and genetic susceptibility modify carcinogenic potency and
cancer risk.” Mutation Research 443: 251-258 Michaud
DS, Spiegelman D, et al..(1999). "Fruit and vegetable intake and
incidence of bladder cancer in a male prospective cohort." J Natl
Cancer Inst 91(7): 605-13. Miller
MC 3rd, Mohrenweiser HW, Bell DA. (2001) “Genetic variability in susceptibility
and response to toxicants.” Toxicol
Lett 120(1-3):269-80 Nijhoff, W.A., T.P.
Mulder et al. (1995).
"Effects of consumption of Brussels sprouts on plasma and urinary
glutathione S-transferase class-alpha and -pi in humans."
Carcinogenesis 16(4): 955-7. Parke,
D.V. (1999). "Antioxidants and disease prevention: mechanisms of
action". Antioxidants in Human Health. CABI Publishing. Perera,
F. P. and Rozen,
R. (2000). "Genetic modulation of homocysteinemia." Semin
Thromb Hemost 26(3): 255-61. Sandhu
MS, White IR, McPherson K. (2001). “Systematic review of the
prospective cohort studies on meat consumption and colorectal cancer
risk: a meta-analytical approach.” Cancer Epidemiol Biomarkers Prev
10(5): 439-46 Schuppe HC, Wieneke P,
Donat S, Fritsche E, Kohn FM, Abel J. (2000). “Xenobiotic metabolism, genetic polymorphisms
and male infertility.” Andrologia 32(4-5): 255-62 Sinha
R, Chow WH, Kulldorff M, Denobile J, Smith
TJ, Yang CS. (2000). "Effect of organosulfur compounds from garlic
and cruciferous vegetables on drug metabolism enzymes.” Drug
Metabol Drug Interact 17(1-4):23-49 Spiteri,
M. A., A. Bianco, et al. (2000). "Polymorphisms at the glutathione S-transferase,
GSTP1 locus: a novel mechanism for susceptibility and development of
atopic airway inflammation." Allergy 55(Suppl 61): 15-20. Steinkellner
H, Rabot S, Freywald C, Nobis E, Scharf G, Chabicovsky M, Knasmuller S,
Kassie F. (2001). “Effects of cruciferous vegetables and their
constituents on drug metabolizing enzymes involved in the bioactivation
of DNA-reactive dietary carcinogens.” Mutat Res 480-481: 285-97 Strange,
R. C., M. A. Spiteri, et al. (2001). "Glutathione-S-transferase family of
enzymes." Mutat Res 482(1-2): 21-6. Sunder-Plassmann,
G., M. Fodinger, et al. (2000). "" J Am Soc Nephrol 11(6): 1106-16. Takeshita,
T. and K. Morimoto (2000). "Accumulation of hemoglobin-associated
acetaldehyde with habitual alcohol drinking in the atypical ALDH2
genotype." Alcohol Clin Exp Res 24(1): 1-7. Ueland,
P. M., Vakevainen
S, Tillonen J, Agarwal DP, Srivastava N, Salaspuro M. (2000). “High
salivary acetaldehyde after a moderate dose of alcohol in
ALDH2-deficient subjects: strong evidence for the local carcinogenic
action of acetaldehyde.” Alcohol
Clin Exp Res 22(4): 195-201 Van Iersel, M.L., H.
Verhagen et al. (1999).
"The role of biotransformation in dietary (anti)carcinogenesis."
Mutation Research 443(1-2): 259-70. Van
Landeghem, G. F., P. Tabatabaie, et al. (1999). "Ethnic variation
in the mitochondrial targeting sequence polymorphism of MnSOD." Hum
Hered 49(4): 190-3. Verhoeff, B. J., M. D.
Trip, et al. (1998).
"The effect of a common methylenetetrahydrofolate reductase
mutation on levels of homocysteine, folate, vitamin B12 and on the risk
of premature atherosclerosis." Atherosclerosis
141(1): 161-6. Wang, X., B. Zuckerman,
et al. (2002)
"Maternal cigarette smoking, metabolic gene polymorphism, and
infant birth weight." Journal of the American Medical Association
287(2): 195 - 202 Willett
WC. (1995). ”Diet, nutrition, and avoidable cancer”. Environ Health
Perspect 103(Suppl 8): 165-170 Williams
JA, Martin FL, Muir GH, Hewer A, Grover PL, Phillips DH. (2000).
“Metabolic activation of carcinogens and expression of various
cytochromes P450 in human prostate tissue.” Carcinogenesis 21(9):
1683-9. Yamauchi
M, Takeda K, Sakamoto K, Searashi Y, Uetake S, Kenichi And H, Toda G.
(2001). “Association of polymorphism in the alcohol dehydrogenase 2
gene with alcohol-induced testicular atrophy.” Alcohol Clin Exp Res
25( Suppl 6): 16-8 Yokoyama
A, Muramatsu T, Ohmori T, Yokoyama T, Okuyama K, Takahashi H, Hasegawa
Y, Higuchi S, Maruyama K, Shirakura K, Ishii H. (1998).
“Alcohol-related cancers and aldehyde dehydrogenase- Zhao
B, Seow A, Lee EJ, Poh WT, Teh M, Eng P, Wang YT, Tan WC, Yu MC, Lee HP.
(2001). “Dietary isothiocyanates, glutathione S-transferase -M1, -T1
polymorphisms and lung cancer risk among Chinese women in Zusterzeel PL, Nelen WL,
Roelofs HM, Peters WH, Blom HJ, Steegers EA. (2000). “Polymorphisms in biotransformation
enzymes and the risk for recurrent early pregnancy loss.” Mol
Hum Reprod 6(5): 474-8 Sen
CK. Nutritional biochemistry of cellular glutathione. Nutr Biochem 1997;8:660-72. Flagg EW, Coates RJ, Jones DP, et al. Dietary glutathione intake and the
risk of oral and pharyngeal cancer. Am
J Epidemiol 1994;139:453-65. Donnerstag B,
Ohlenschläger, Cinatl J, et al. Reduced glutathione and S-acetylglutathione as selective
apoptosis-inducing agents in cancer therapy. Cancer
Lett 1996;110:63-70. Trickler D, Shklar G, Schwartz J. Inhibition of oral carcinogenesis by
glutathione. Nutr Cancer
1993;20:139-44. Julius M, Lang C, Gleiberman L, et al. Glutathione and morbidity in a
community-based sample of elderly. J Clin Epidemiol
1994;47:1021-6. Hagen TM, Wierzbicka GT, Sillau AH, et al. Fate of dietary glutathione:
disposition in the gastrointestinal tract. Am
J Physiol 1990;259(4Pt1):G530-5. Favilli F, Marraccini P, Iantomasis T, Vincenzini MT. Effect
of orally administered glutathione on glutathione levels in some organs
of rats: role of specific transporters. Br
J Nutr 1997;78:293-300. Witschi A, Reddy S, Stofer B, Lauterburg BH. The systemic availability of
oral glutathione. Eur J Clin Pharmacol
1992;43:667-9. Hunjan MK, Evered DF. Absorption of glutathione from the
gastro-intestinal tract. Biochim
Biophys Acta 1985;815:184-8. Bunin AIa, Filina AA, Erchev VP. A glutathione deficiency in open-angle
glaucoma and the approaches to its correction. Vestn Oftalmol 1992;108:13-5 [in Russian]. Amores-Sanchez MI, Medina MA. Glutamine, as a precursor of glutathione, and
oxidative stress. Mol Genet
Metab 1999;67:100-5. Vendemiale G, Altomare E, Trizio T, et al. Effects of oral S-adenosyl-L-methionine
on hepatic glutathione in patients with liver disease. Scand
J Gastroenterol 1989;24:407- Bounous G, Gervais F, Amer V, et al. The
influence of dietary whey protein on tissue glutathione and the diseases
of aging. Clin Invest Med
1989;12:343-9. Molloy J, Martin JF, Baskerville PA, et al. S-nitrosoglutathione
reduces the rate of embolization in humans. Circulation
1998;98:1372-5. Smyth JF, Bowman A, Perren T, et al. Glutathione
reduces the toxicity and improves quality of life of women diagnosed
with ovarian cancer treated with cisplatin: results of a double-blind,
randomised trial. Ann Oncol
1997;8:569-73. Cascinu S, Cordella L, Del Ferro E, et al. Neuroprotective effect of
reduced glutathione on cisplatin-based chemotherapy in advanced gastric
cancer: a randomized double-blind placebo-controlled trial. J Clin Oncol 1995;13:26-32. Sechi G, Deledda MG, Bua G, et al. Reduced intravenous glutathione in the
treatment of early Parkinson’s disease. Prog Neuropsychopharmacol Biol Psychiatry
1996;20:1159-70. Ceriello A, Giugliano D, Quatraro A, Lefebvre PJ. Anti-oxidants show an
anti-hypertensive effect in diabetic and hypertensive subjects. Clin
Sci
1991;81:739-42. Lenzi A, Picardo M, Gandini L, et al. Glutathione
treatment of dyspermia: effect on the lipoperoxidation process. Hum
Reprod
1994;9:2044-50. Lenzi A, Culasso F, Gandini L, et al. Placebo-controlled,
double-blind, cross-over Testa B, Mesolella M, Testa D. Glutathione in
the upper respiratory tract. Ann
Otol Rhinol Laryngol 1995;104:117-9. Dalhoff K, Ranek L, Mantoni M, Poulsen HE. Glutathione treatment of
hepatocellular carcinoma. Liver
1992;12:341-3. Garcia-Giralt E, Perdereau B, Brixy F, et al. Preliminary study of
glutathione, L-cysteine and anthocyans (Recancostat Compositum™) in
metastatic colorectal carcinoma with malnutrition. Seventh International
Congress on Anti-Cancer Treatment, February 3-6, 1996, Jones DP, Coates RJ, Flagg EW, et al. Glutathione
in foods listed in the National Cancer Institutes Health Habits and
History Food Frequency Questionnaire. Nutr
Cancer 1995;17:57–75. White AC, Thannickal VJ, Fanburg BL. Glutathione deficiency in human
disease. J Nutr Biochem
1994;5:218–26. Nemets B, Stahl Z, Belmaker RH. Addition
of omega-3 fatty acid to maintenance medication treatment for recurrent
unipolar depressive disorder. Am J Psychiatry 2002;159:477–9.
|
|